Aid in the early detection of lung cancer in high‑risk individuals
Provide an effective assessment of lung cancer risk in indeterminate pulmonary nodules (IPNs)
The EarlyCDT® Lung test detects the presence of autoantibodies generated by the body’s immune system, a natural defense against cancer cells. This aids in the early detection of lung cancer in high-risk patients.
A randomised controlled trial of 12,000 people in Scotland at high risk of developing lung cancer showed that after two years of follow-up, participants in the EarlyCDT® Lung intervention group saw a significant reduction (37%) in late-stage presentation compared to the control group subject to standard clinical practice.2
These landmark findings are likely to have globally significant implications for the early detection of lung cancer. A simple blood test, followed by CT scans, is able to increase the number of patients diagnosed at an earlier stage of the disease, when surgery is still possible and prospects for survival much higher.
Best Medical Opinion
Yefe Nof St 1
Givatayim, Israel
Diamedix Diagnostica
15A Fabrica de Glucoza St.
A4 Building
Bucharest, 2nd District 020331
Romania
Weavegen Pte. Ltd
1 Coleman Street
#10-06 The Adelphi
Singapore, 179803
Sabartech S.L.
Parque Científico
Universidad de Valencia,
C/Catedrático Agustín
Escardino, 9, 46980
Paterna, Valencia
Spain
Cambridge Clinical
Laboratories Limited
Park House, Winship Road
Milton, Cambridge,
Cambridgeshire CB24 6BO
United Kingdom
MediCity, D6 Thane Road
Nottingham, NG90 6BH
United Kingdom
Curtiusstrasse 27
23568 Lübeck
Germany